HUTCHMED gains wider China drug coverage on NRDL, insurance

    Telix Pharmaceuticals updates Illuccix China trial, FDA plans

    Telix (ASX: TLX, NASDAQ: TLX) provided a precision medicine portfolio update on Dec 21, 2025 covering three PET imaging candidates. TLX591-CDx (Illuccix): Phase 3 China study (n=140) met its primary endpoint with overall patient-level PPV 94.8% (95% CI: 85.9%, 98.2%), region-level PPV 100% in prostate bed and non-bone metastases, and…

    Read More
    Jeff Bezos agrees with OpenAI’s Sam Altman: We’re in an AI bubble. But Amazon's founder says the benefits will be ‘gigantic’

    Jeff Bezos agrees with OpenAI’s Sam Altman: We’re in an AI bubble. But Amazon’s founder says the benefits will be ‘gigantic’

    Jeff Bezos joined Sam Altman in admitting the existence of an AI bubble—but Amazon’s founder sees upside. Recently, many AI-related companies have seen voracious optimism and spikes in valuations. In August, the OpenAI CEO told reporters the AI market was in a bubble. When bubbles happen, “smart people get overexcited about a kernel of truth,” Altman…

    Read More
    Chinese stocks: 90% of US investors set to increase exposure, Morgan Stanley says

    Chinese stocks: 90% of US investors set to increase exposure, Morgan Stanley says

    US investors are showing the highest level of interest in Chinese stocks in five years, and their return to China’s market is just “starting” despite some lingering reasons for caution, according to Morgan Stanley. More than 90 per cent of investors had “explicit willingness to increase their exposure to China’s market, the highest level since…

    Read More